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Abstract: Nitric oxide (NO) is a structurally simple, highly versatile molecule that was 
  originally discovered over 30 years ago as an endothelium-derived relaxing factor. In addition to 
its vasorelaxing effects, NO is now recognized as a key determinant of vascular health, exerting 
antiplatelet, antithrombotic, and anti-inflammatory properties within the vasculature. This short-
lived molecule exerts its inhibitory effect on vascular smooth muscle cells and platelets largely 
through cyclic guanosine monophosphate-dependent mechanisms, resulting in a multitude of 
molecular effects by which platelet activation and aggregation are prevented. The biosynthesis 
of NO occurs via the catalytic activity of NO synthase, an oxidoreductase found in many cell 
types. NO insufficiency can be attributed to limited substrate/cofactor availability as well as 
interactions with reactive oxygen species. Impaired NO bioavailability represents the central 
feature of endothelial dysfunction, a common abnormality found in many vascular diseases. In 
this review, we present an overview of NO synthesis and biochemistry, discuss the mechanisms 
of action of NO in regulating platelet and endothelial function, and review the effects of vascular 
disease states on NO bioavailability.
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Introduction
Nitric oxide (NO) is a structurally simple molecule that exerts effects on a wide vari-
ety of actions in the vasculature. NO was first discovered in 1980 by Furchgott and 
Zawadzki1 as an endothelium-derived relaxing factor, it has been recognized as a key 
determinant of vascular homeostasis, regulating several physiological properties of 
the blood vessel, including vasodilation, vascular permeability, and antithrombotic 
properties.2 The bioavailability of NO represents a central feature of the normal 
vascular phenotype required for maintaining vasodilator tone and inhibiting platelet 
activation, thereby preventing thrombosis and its clinical vascular consequences. 
Decreased production or increased metabolism of NO may lead to NO insufficiency 
within the vasculature and its pathobiological consequences. This review begins with 
an overview on NO’s ability to modulate vascular tone and platelet activity, discusses 
the biochemical pathways involved in metabolism of NO, briefly summarizes factors 
controlling NO synthase (NOS) activity, discusses the impact of vascular patholo-
gies on NO and vice versa, and comments on pharmacological therapies for restoring 
vascular NO and their therapeutic utility.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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vascular actions of nitric oxide
vascular tone
NO is a major regulator of vascular homeostasis, acting in 
various ways to regulate vascular tone. Low levels of NO 
produced by the endothelial cell play a key role maintaining 
vasorelaxation by exerting its effects on vascular smooth 
muscle cells (VSMCs), the contractile state of which defines 
vascular tone. NO produced within the cytosol of endothe-
lial cells diffuses rapidly into adjacent VSMCs, exerting 
paracrine effects by activating soluble guanylyl cyclase to 
increase the synthesis of 3,5-cyclic guanosine monophos-
phate (cGMP). NO also decreases cytosolic Ca2+ concentra-
tion through inhibition of voltage-gated Ca2+ channels3 and 
activates protein kinases that phosphorylate proteins in the 
sarcoplasmic reticulum, as well as Ca2+-dependent potas-
sium channels.3 Reduction in cytosolic Ca2+ concentration 
results in inhibition of calcium-calmodulin myosin light 
chain kinase complex formation in the VSMC, promoting 
vasorelaxation.4
Low levels of NO released by endothelial cells are criti-
cal for the maintenance of basal vascular tone. The synthesis 
of endothelial NO is increased in response to biochemical 
stimuli, including thrombin, adenosine diphosphate (ADP), 
serotonin, acetylcholine, and bradykinin; as well as mechani-
cal stimuli, including shear stress and cyclic strain. Studies 
have previously shown that inhibition of NO synthesis in the 
vasculature may lead to hypertension5 or ischemic stroke,6 
likely, in part, through its effects not only on vascular tone, 
but also on thrombotic potential.7
In addition to the ability of NO to regulate basal vas-
cular tone, NO has also been found to influence stimulated 
endothelial release of tissue-type plasminogen activator 
(t-PA). Tissue-type plasminogen activator acts as the primary 
activator of endogenous fibrinolysis by converting the inac-
tive proenzyme plasminogen to the active enzyme plasmin. 
Studies regarding the release of t-PA have thus far been 
conflicting, with some studies showing an inhibitory effect 
of NO on t-PA release8,9 and another showing the opposite.10 
The role of NO in modulating t-PA still remains unclear; 
however, a possible explanation for the inhibitory effect of 
NO on t-PA release may be attributed to acute NO deprivation 
invoking a protective response resulting in greater endothelial 
t-PA release. Conversely, a possible explanation supporting 
NO-induced t-PA release as seen in Giannarelli’s study may 
be due to the lower   concentration of l-NG-monomethyl argi-
nine citrate, a NOS inhibitor, 1 mg/min, compared with the 
2 previously mentioned studies by Smith et al8 and Pretorius 
and Brown,9 5 mg/min and 3 mg/min, respectively. Further 
studies are needed to elucidate NO’s role in endothelial t-PA 
modulation.
Platelet function and formation
NO plays a key role in maintaining vascular integrity and 
blood flow by modulating platelet–endothelial interactions.11 
Although platelets play an important role in hemostatic 
plug formation and wound healing, hyperreactivity can lead 
to vascular thrombosis and its clinical sequelae.7 Platelets 
normally circulate in an inactive state, suppressed by 3 
biochemical systems: prostacyclin, ecto-AD(T)Pase/CD39, 
and NO.12 Prostacyclin, the main product of arachidonic 
acid metabolism in endothelial cells,13 inhibits platelets via 
cAMP-dependent mechanisms that include direct inhibition 
of Ca2+ mobilization and granule release.14 Ecto-AD(T)Pase 
is responsible for inhibition of platelet function by decreas-
ing ADP-induced platelet aggregation15 and also indirectly 
by inhibiting the thromboxane A2 (TXA2) receptor16 (see 
later).
Calcium plays a central role as a second messenger 
in platelets. Concentrations within resting platelets are 
maintained between 50 and 100 nM, and upon activation, 
can achieve levels as high as 1 mM.17 An increase in Ca2+ 
concentration within platelets leads to cytoskeletal rear-
rangement, shape change, and platelet granule secretion, 
ultimately resulting in aggregation.12 Platelet-associated 
Ca2+-binding proteins include alpha-helix, loop, second 
alpha-helix (EF-hand) proteins, and Ca2+-phospholipid 
binding proteins.18 Calmodulin is an EF-hand protein that 
binds to alpha-granules and is associated mechanistically 
with the Ca2+-calmodulin-induced phosphorylation of myo-
sin light chain contributing to platelet granule secretion.19,20 
Synaptotagmin, a Ca2+-phospholipid binding protein, 
has been associated with the regulation of dense granule 
secretion,21 further contributing to platelet activation and 
aggregation.
NO exerts its inhibitory effects on platelets via cGMP 
production and a secondary Ca2+-adenosine triphosphatase 
(ATPase)-dependent refilling of Ca2+ stores.22 Increased 
NO-stimulated guanylyl cyclase activity results in decreased 
intracellular Ca2+ levels through the inhibition of receptor-
mediated Ca2+ release from the dense tubular system, an 
increased rate of Ca2+ extrusion, and decreased Ca2+ entry 
from the extracellular environment. In addition, NO increases 
sarcoplasmic reticulum Ca2+-ATPase activity via cGMP-
dependent protein kinase G-mediated phosphorylation of 
phosphlamban,23 which results in lower Ca2+ available for 
participating in activation/aggregation mechanisms.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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NO’s ability to regulate cGMP is the principal deter-
minant of its platelet inhibitory actions. The mechanisms 
by which cGMP-associated inhibition of platelets occurs 
include not only a decrease in intracellular Ca2+ concentra-
tion by the mechanisms described earlier, but also impaired 
expression of the active (fibrinogen binding) conforma-
tion of glycoprotein (GP) IIb/IIIa and decreased platelet-
bound fibrinogen. For hemostatic plug formation to take 
place, platelets must interact with one another by forming 
crosslinks with cell surface receptors, thereby leading 
to aggregation. Fibrinogen, a bivalent molecule, bridges 
adjacent activated platelets via the platelet GPIIb/IIIa 
integrin receptors. Cyclic GMP reduces the total number of 
conformationally active GPIIb/IIIa receptors on the platelet 
surface via inhibition of thrombin-mediated activation of 
phophoinositide 3-kinase24 and increases in the dissociation 
constant between fibrinogen and the GPIIb/IIIa receptor, 
resulting in unfavorable conditions for platelet aggrega-
tion. The resulting decrease in fibrinogen binding has been 
shown to be dose-dependent and strongly correlated with 
NO-dependent cGMP production.25 TXA2, an eicosanoid 
produced via arachadonic acid metabolism within the 
platelet, contributes to platelet aggregation by mediating 
platelet GPIIb/IIIa expression. The TXA2 receptor serves as 
a substrate for cGMP-dependent protein kinase and cGMP 
itself,16 leading to impaired receptor function, thereby rep-
resenting another mechanism by which NO inhibits platelet 
activation. Furthermore, cGMP regulates the expression of 
the platelet (and endothelial) surface adhesion molecule 
P-selectin, in part, through the down-regulation of protein 
kinase C (PKC).26
NO has also been shown to modulate megakaryocyte 
apoptosis. Megakaryocytes are responsible for platelet 
production, and factors affecting their viability may 
ultimately affect platelet formation (thrombopoiesis). 
Battinelli and Loscalzo27 investigated the role of NO on 
apoptosis in megarkaryocyte cell lines and found that NO 
induced apoptosis. They reported that both endogenous and 
exogenous sources of NO regulated apoptosis in Meg-01 
and human erythroleukemia megakaryocytoid cell lines 
via modulation of the Bcl-2 family of proteins. This same 
group further investigated the role of NO-induced apop-
tosis on platelet formation by exploring the role of NO in 
the terminal stages of megakaryocytopoiesis. They found 
that NO-induced apoptosis in megakaryocytes resulted 
in platelet production.28 Thus, NO has effects on platelet 
production from megakaryocytes as well as on platelet 
function itself.
Nitric oxide synthesis and biochemistry
Nitric oxide synthesis
NO synthesis occurs in a range of cell types and tissues within 
the vasculature, including platelets, macrophages, and the 
vascular endothelium.29 A class of enzymes known as NOS 
includes neuronal NOS (nNOS), endothelial NOS (eNOS), 
and inducible NOS (iNOS), all sharing between 50% and 
60% sequence homology.30 All 3 isoforms catalyze a 5-step 
electron oxidation of the terminal guanidino nitrogen atom of 
l-arginine to produce l-citrulline and NO.31 Enzyme activity 
requires flavin mononucleotide, flavin adenine dinucleotide, 
tetrahydrobiopterin (BH4), Ca2+-calmodulin, and heme, 
which serve as cofactors, along with nicotinamide adenine 
dinucleotide phosphate (NADPH) and molecular oxygen, 
which serve as cosubstrates.32
NO is an uncharged radical molecule approximately 
70 times more soluble in hydrophobic environments than in 
water, enabling it to diffuse readily across cell membranes. 
Owing to its relatively short half-life, NO acts primarily 
in local environments. After synthesis, NO diffuses across 
biological membranes into specific target cells where it 
stimulates guanylyl cyclase to produce cGMP from guanos-
ine triphosphate (GTP).33 Biological responses mediated by 
cGMP second messenger pathways described earlier are the 
principal, but not exclusive, action of NO.34
The 3 NOS isoforms are characterized by their site of 
synthesis, pattern of expression, and Ca2+ dependency: NOS 
I or nNOS is expressed primarily in neurons; NOS II or 
iNOS, initially isolated from cytokine-induced macrophages, 
is now recognized as located in macrophages, neutrophils, 
platelets, and VSMCs, as well as in other nonvascular cells; 
NOS III or eNOS is constitutively expressed in endothelial 
cells.35 Each NOS isoform is comprised of an N-terminal 
oxygenase domain and a C-terminal reductase domain with a 
calmodulin recognition sequence between the 2.36 NOS activ-
ity is regulated by changes in intracellular Ca2+ concentration 
that affect the binding of calmodulin for efficient electron 
transfer from NADPH to the heme iron, which then catalyzes 
NO synthesis.37 The constitutively expressed NOS isoforms 
(nNOS and eNOS) are membrane-associated and bind cal-
modulin in a rapidly reversible and strongly   Ca2+-dependent 
manner to regulate their activity.
When endothelial cells are activated by a   receptor-mediated 
agonist, such as acetylcholine or bradykinin, or mechanical 
stimuli, such as shear stress, Ca2+ is transiently released 
from intracellular stores via a second messenger cascade 
involving inositol triphosphate, resulting in   Ca2+-calmodulin 
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by eNOS is transient, paralleling intracellular Ca2+ levels.38 
Endothelial NOS produces NO in the nanomolar range, a 
concentration that decreases with decreasing intracellular Ca2+ 
concentration, associated with the cytoprotective effects of 
NO and effective regulation of vascular tone. Unlike eNOS 
and nNOS, iNOS is less susceptible to changes in intracel-
lular Ca2+ concentration, binding more avidly to calmodulin 
at the low Ca2+ concentrations found in resting cells.39 NO 
production by iNOS is regulated at the transcriptional level, 
stimulated mainly by cytokines and microbial products 
(endotoxin),40 resulting in NO production in the micromolar 
range; these concentrations have been associated with mito-
chondrial membrane pore transition and caspase activation, 
resulting in apoptosis and necrosis.41 These elevated levels of 
NO are associated with the general cytotoxic effects of NO.
Nitric oxide bioreactivity
NO can exist in 3 closely interrelated redox forms: the free 
radical (NO.), nitrosonium (NO+) resulting from a 1-electron 
oxidation of NO., and nitroxyl anion (NO−) resulting from a 
1-electron reduction of NO..42 Each redox form has distinct 
chemical properties and reactivity. The major metabolic 
product of NO in aqueous solutions is nitrite. These NO 
species (NOx) (reactive nitrogen species) and, in some cases, 
NO itself, can interact with molecular oxygen, thiols, reduced 
hemoproteins, and redox metals that conspire to determine 
its half-life and metabolism in biological systems. Some of 
these interactions include the reaction of NO with heme iron 
that leads to guanylyl cyclase activation resulting in cGMP 
formation; and the reaction of nitrosonium with – SH group-
containing biomolecules in the presence of molecular oxygen 
to produce S-nitrosothiols (RSNO). S-nitrosothiols are rela-
tively stable compared with NO and may represent a storage 
pool for bioavailable NO.43,44 S-nitrosoalbumin accounts for 
the majority of RSNO in human plasma, and, along with 
other S-nitrosothiols, protects NO from inactivation with 
an approximate half-life ranging from 15 to 40 minutes in 
circulating blood. Cysteine is the sole thiol source in proteins 
and also constitutes the reactive thiol residue of glutathione. 
S-nitrosoglutathione (GSNO) possesses an approximate 
half-life of 8 minutes in the circulating blood. Biological 
actions of RSNO may be associated with heterolytic as well 
as homolytic mechanisms of decomposition resulting in 1 
of the 3 NO redox forms. Heterolytic pathways of RSNO 
decomposition have been associated with many biological 
activities of NO.45 The substantially slower reaction rates 
between superoxide and RSNO compared with superoxide 
and NO suggest that the RSNO stabilizes NO protecting it 
from oxidative inactivation and thereby increasing its bio-
availability.46 In addition, as many S-nitrosoproteins47 form 
via trans-S-nitrosation from GSNO, GSNO reductase48 is an 
important regulator of the bioavailability of (RS)NO.
The ability of NO to form a complex with hemoglobin 
(Hb) is a recent emerging concept unveiling a vital physi-
ological function in the setting of hypoxic vasodilation. Hb 
becomes S-nitrosylated on a specific cysteine residue on 
the β-chain (βCys93) as red blood cells become oxygen-
ated in the lungs, resulting in SNO-Hb formation. This 
complex, SNO-Hb, exists in 2 conformational states, the 
R-state (relaxed and unreactive state, high oxygen affinity 
Hb conformation) and the T-state (tense reactive state, low 
oxygen affinity Hb conformation) in which SNO-Hb can 
rapidly react with thiols and elicit a vasodilatory response 
within the vasculature.49,50 Dysfunction in this pathway has 
been shown to be associated with congestive heart failure,51 
diabetes,52 and pulmonary hypertension.53 This SNO-Hb 
paradigm, recently reviewed by Allen et al,54 could have 
therapeutic implications for diseases involving abnormal 
microcirculatory perfusion.
NO can react with molecular oxygen and several reactive 
oxygen species (ROS), as shown in Figure 1, including super-
oxide anion (O2
−.), hydrogen peroxide (H2O2;   indirectly), and 
hydroxyl radical (.OH), to limit its bioactivity. Both endothelial 
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Figure 1 Biological reactions of nitric oxide. The free radical nitric oxide (NO.) 
can react with many constituents within the vasculature that affect its bioavailability. 
NO. can undergo oxidative inactivation (reactions shown in dashed lines) to form 
nitrite (NO2
−) and nitrate (NO3
−). Other biologically relevant mechanisms include 
indirect interaction with hydrogen peroxide (H2O2) products (via Fenton chemistry) 
resulting in nitrous acid (HNO2) formation. Another key reactive oxygen species in 
the vasculature contributing to NO insufficiency is superoxide (O2
−.) which reacts 
with NO to form peroxynitrite (OONO−). S-nitrosothiols (RSNO) formation via 
OONO−  interaction  with  thiols,  and  nitrosyl-heme/S-nitroso-albumin  formation 
represent ways in which NO can be protected from oxidative inactivation, thereby 
increasing overall bioavailability.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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cells and macrophages are sources of these ROS. NO reacts 
with O2
−. to form peroxynitrite (OONO−)55 at an almost near-
diffusion-limited rate of 6.7 × 109 M−1 s−1. This rate of peroxyni-
trite formation exceeds the rate constant for the reduction of 
superoxide to hydrogen peroxide by superoxide dismutase, the 
principal antioxidant responsible for O2
−. metabolism.56 Among 
its deleterious effects are included loss of bioactive NO and 
direct cytotoxic effects resulting in apoptosis or necrosis.57
Through the reduction of H2O2 via Fenton chemistry, a 
hydroxyl radical, .OH, can react readily with NO, decreas-
ing its bioavailability. ROS in the vessel wall can react with 
polyunsaturated fatty acid species in the low density lipo-
protein (LDL) particle, initiating lipid peroxidation, which 
results in the formation of oxidized LDL.58 Oxidized LDL 
has been shown to limit NO bioavailability by a number of 
mechanisms. For example, Chen et al59 investigated the role 
of the l-arginine-NO pathway in oxidized LDL-mediated 
platelet activation, and found that oxidized LDL decreased 
l-arginine uptake, eNOS expression, cGMP production, and 
subsequent NO (nitrite) production.
Nitric oxide synthase regulation
The activity of NOS is regulated by a number of tran-
scriptional and posttranslational mechanisms as shown 
in Figure 2. Some modes of regulation are specific to a 
particular NOS isoform, whereas others are shared between 
them. Factors regulating NOS activity affect NO bioavailabil-
ity and, ultimately, target cell function and phenotype. One 
major factor regulating NOS activity is feedback inhibition by 
NO itself. NOS isoforms are hemoproteins, readily binding 
NO to their heme prosthetic groups.60 NO binds reversibly 
to ferric or ferrous heme proteins within seconds after the 
initiation of NO synthesis, resulting in temporary eNOS 
inactivation.60,61 These inactive complexes have the ability 
to reactivate, producing NO when NO dissociates from the 
heme iron. Studies have shown that 70%–90% of iNOS and 
nNOS are present in their inactive ferrous-NO forms during 
steady-state catalysis,60,61 resulting in NOS activity that is 
only a fraction of its maximal activity. Ferrous-NO can react 
with O2 to participate in NO generation; ferrous-NO complex 
formation results in NO synthesis rates proportional to the 
O2 concentration throughout the physiological range due 
primarily to NOS–NO complex dissociation, which itself is a 
function of O2 concentration rather than the intrinsic affinity 
of the NOS heme iron for O2.60
NOS activity can also be regulated by BH4 levels. BH4 
is a critical cofactor required for NO synthesis owing to 
its ability to couple heme iron reduction to NO synthesis. 
Subsaturating levels of BH4 have been shown to result in NOS 
inhibition by NO,62 occurring over several minutes. Possible 
mechanisms of inactivation include uncoupled O2 reduction 
to superoxide that occurs in the absence of sufficient BH4, 
dimer dissociation,62 or NO binding to heme.63 Dimeriza-
tion of NOS is essential for its biological activity, and BH4 
interacts with residues on both subunits of the dimer and 
also forms hydrogen bonds with the heme site. Dimerization 
activates NOS by sequestering heme from solvent, creating 
favorable conditions for l-arginine and BH4 binding, and also 
allows electrons from reductase domain flavins to transfer to 
the oxygenase domain heme.64,65 NO can inhibit expression 
of NOS, limiting assembly of dimeric NOS by preventing 
heme insertion and decreasing heme availability.66
Another cofactor essential for NO biosynthesis via 
NOS is the substrate, l-arginine. l-arginine is converted to 
l-citrulline and NO via a 5-step electron oxidation of the ter-
minal guanidino-nitrogen atom of l-arginine. An experiment 
of nature leading to l-arginine deficiency also supports the 
importance of this amino acid in NO and vascular homeo-
stasis. In the genetic disorder, lysinuric protein intolerance, 
a mutation in the SLC7A7 gene leads to impaired l-arginine 
uptake by cells.67 The resulting deficiency of l-arginine 
transport led to significantly reduced NO synthesis, impaired 
endothelium-dependent dilation,68 and enhanced platelet 
activation and intravascular coagulation,69 highlighting the 
importance of endogenous l-arginine in NO production and 
its key vascular actions.70
Administration of l-arginine has proven to be protec-
tive for endothelial function in animal studies.71 Both acute 
and chronic administration of l-arginine in cholesterol-fed 
animals results in improvement of endothelium-dependent 
dilation.72 The beneficial effects of l-arginine administration 
have also been demonstrated in other disease states, such as 
hypertension,73 coronary atherosclerosis,74 and transgenic-
knockout sickle mice.75 l-arginine supplementation in hyper-
cholesterolemic rabbits resulted in attenuation of aorta intima/
media thickening and increased eNOS expression compared 
with controls.76 A randomized, double-blind, placebo-con-
trolled study administering oral l-arginine to patients with 
heart failure for 6 weeks resulted in improved forearm blood 
flow, increased distances during a 6-minute walk test, as well 
as improved arterial compliance compared with controls.77 
Most of the previously mentioned studies showing benefi-
cial effects of l-arginine supplementation were short-term 
studies. Long-term administration of l-  arginine in patients 
with peripheral artery disease showed the   contrary data. 
Wilson et al78 conducted a randomized clinical trial of oral Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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l-arginine vs placebo for 6 months in patients with intermit-
tent claudication due to peripheral artery disease. They found 
that long-term l-arginine supplementation did not increase 
NO synthesis or improve vascular reactivity.78 In another 
clinical study involving patients with stable coronary heart 
disease, l-arginine supplementation failed to show any 
significant improvement of endothelium-dependent vasodi-
lation or blood flow as compared with placebo.79 l-arginine 
supplementation has also been shown to have no significant 
effect on endothelial function, blood flow, markers for oxida-
tive stress, or exercise performance in patients with coronary 
heart disease and stenosis80 as well as no benefit in patients 
with coronary artery disease after the onset of myocardial 
infarction with respect to death, reinfarction, or recurrent 
myocardial ischemia.81 The mechanism by which l-arginine 
administration exerts its beneficial effects in various disease 
states is unclear; however, future benefits occurring via the 
enhancement of vascular NO synthesis has been supported 
NO
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Figure 2 Factors and actions affecting NO and platelet function. Nitric oxide (NO) exerts inhibitory effects (dashed lines) on platelets through a variety of mechanisms. The 
predominant pathway involves generation of NO from l-arginine by endothelial nitric oxide synthase (eNOS) and cyclic guanosine monophosphate (cGMP) formation via 
guanylyl cyclase activation by NO. Nitric oxide inhibits platelet activation and aggregation by decreasing intracellular Ca2+ concentration, glycoprotein (GP) iiB/iiia expression, 
and platelet association with fibrinogen. cGMP, formed from NO’s catalytic effect on guanylyl cyclase, also inhibits platelets by decreasing thromboxane A2 expression as 
well as expression of the platelet surface adhesion molecule, P-selectin. endothelial NOS activity is regulated by several transcriptional, posttranslational, and physiological 
factors that either result in inactivation or upregulation, ultimately affecting NO bioavailability. Factors decreasing eNOS (dashed lines) activity include NO itself, via negative 
feedback, reduced substrate and/or cofactor bioavailability, hypoxia, and oxidized low density lipoprotein (LDL). By contrast, laminar shear stress, cell growth, and H2O2 have 
been shown to increase eNOS activity (solid lines), cGMP formation, and bioavailable NO.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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by corresponding upregulation of the NO-cGMP pathway in 
endothelial cells of the myocardium.82
In addition to limited cofactor availability affecting 
eNOS activity and NO synthesis, a naturally occurring 
inhibitor, asymmetric dimethylarginine (ADMA), was first 
identified in 1992.83 ADMA is synthesized by methylation 
of arginine residues via N-methyltransferases, which utilize 
S-adenosylmethionine as a methyl group donor. It is released 
when the methylated arginine residues are degraded into their 
amino acid components during hydrolytic protein turnover.84 
The physiological effects of ADMA were first characterized 
in vascular rings where ADMA inhibited NOS resulting 
in decreased NO synthesis and vasoconstriction.83 Plasma 
ADMA concentrations are elevated in many disease states, 
including hypercholesterolemia,85 hyperhomocysteinemia,86 
hypertension,87 pulmonary hypertension,88 stroke,89 and 
diabetes mellitus.90 A recent study by Ding et al91 identified 
a novel 4-nucleotide deletion/insertion variant in the dim-
ethylarginine dimethylaminohydrolase I (DDAH1) gene, an 
important gene in the major pathway for ADMA clearance, 
associated with increased susceptibility to thrombotic stroke 
and coronary heart disease. Overexpression of DDAH1 has 
been shown to protect against cerebral arteriole hypertrophy 
and to improve vascular smooth muscle function.92 In a study 
investigating the effects of ADMA on shear stress-dependent 
dilation of skeletal muscle arterioles, Toth et al93 showed 
that ADMA inhibited shear stress-induced NO release and 
vasodilation, and, instead, stimulated O2
−. release, favoring 
the development of increased shear stress, increased vascular 
resistance, and, ultimately, hypertension.
The association between plasma ADMA concentration 
and endothelial dysfunction contributing to cardiovascular 
disease has lead to its emerging as a novel risk factor and 
potential pharmacotherapeutic target. Clinical studies involv-
ing l-arginine supplementation in hypercholesterolemic sub-
jects have shown improved endothelial function,94 improved 
vasomotor responses to methacholine,95 and improved flow-
mediated dilation96 in the brachial artery. Studies involv-
ing l-arginine supplementation in subjects with arterial 
hypertension have also shown increases in forearm blood 
flow,77 improvement in coronary small-vessel endothelial 
function,97 and decreased blood pressure via increased NO 
production.98
In addition to posttranslational mechanisms regulating 
NOS activity, there are many transcriptional and post-
transcriptional regulators of the enzyme. Posttrascriptional 
regulators of eNOS include phosphorylation by several 
kinases regulating protein–protein interactions and the avail-
ability of cofactors and substrates,99 localization of eNOS 
to the caveolae, and dissociation from caveolin-1.100 Other 
posttranslational modifications regulating eNOS expression 
include myristoylation and palmitoylation, which are required 
for the targeting of eNOS to the caveolae.101,102
Several physiological and pathophysiological stimuli have 
been indentified that affect eNOS mRNA expression and 
stability. Stimuli shown to increase eNOS expression include 
shear stress, cell growth, and hydrogen peroxide. By contrast, 
hypoxia and oxidized LDL can decrease eNOS expression. 
One of the more potent regulators of eNOS expression is 
laminar shear stress. Both in vivo103 and in vitro104,105 studies 
have shown an upregulation in eNOS expression due to shear 
stress. Weber et al106 conducted in vitro experiments using 
bovine aortic endothelial cells and found that shear stress 
increased expression of eNOS mRNA with long poly(A) tails 
resulting in a 3-fold increase in half-life compared with cells 
not exposed to shear (ie, cultured under static conditions). 
Their results support the concept that shear stress modu-
lates eNOS mRNA stability and translation via increased 
3′-adenylation due to a dose-dependent effect of shear on 
eNOS polyadenylation, also observed in vivo,107 and shown 
to be dependent on the duration of shear stress. Laminar shear 
stress resulted in an early increase in eNOS mRNA expression 
and a sustained stabilization of eNOS mRNA, as evidenced 
by a 4-fold to 5-fold increase in transcription and an increase 
in mRNA half-life by more than 3-fold compared with cells 
cultured under static conditions.108 Davis et al108 identified 
two pathways involving c-src that lead to an increase in eNOS 
mRNA transcription and mRNA stability. The increase in 
eNOS mRNA transcription involved the Raf, Ras, and ERK 
1/2 pathway, whereas the stabilization of eNOS in response to 
shear stress was completely abrogated by the c-src inhibitor 
PP1, but not altered by Ras or ERK inhibition, supporting the 
existence of separate pathways responsible for the increase 
in transcription and for mRNA stabilization.
More recent studies identified miR-21 as a regulator 
of eNOS activity and apoptosis in human umbilical vein 
endothelial cells (HUVEC). MicroRNAs are short RNA 
molecules averaging 22 nucleotides that bind to comple-
mentary sequences in the 3´-untranslated region (UTR) of 
mRNA transcripts, leading to posttranscriptional regulation 
(degradation of mRNAs) of genes involved in differentia-
tion, proliferation, and apoptosis. Through the utilization 
of a TaqMan low density array and qRT-PCR, miR-21 was 
shown to be increased 5.2-fold in HUVECs exposed to 
unidirectional shear stress compared with cells grown under 
static conditions. HUVECs overexpressing miR-21 had Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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decreased apoptosis and increased eNOS phosphorylation 
and NO production.109 miR-21 also suppressed phosphatase 
and tensin (PTEN), which is a tumor suppressor gene, and has 
been shown to play an important role in regulating apoptosis 
via antagonism of the PI3K/Akt pathway.110 The authors 
concluded that miR-21 overexpression in HUVECs involves 
regulation of PTEN expression and subsequent changes in 
the PI3K/Akt/eNOS pathway.109
Cell growth has also been shown to be a potent stimulus 
for eNOS expression, both in vitro111 and in vivo.112 In vitro 
studies using bovine aortic endothelial cells (BAECs) revealed 
a 3-fold increase in eNOS protein level, a 6-fold increase in 
mRNA expression, and a 3-fold increase in eNOS activity 
in proliferating cells compared with confluent cells.111 The 
authors concluded that these results were due either to an 
increase in transcription or a decrease in degradation of eNOS 
mRNA. In a follow-up study, Searles et al113 investigated the 
factors responsible for changes in eNOS expression during 
cell proliferation. Using BAECs, they showed steady-state 
eNOS mRNA levels to be 4-fold higher in proliferating cells 
compared with confluent cells. A nuclear run-on analysis 
was performed to determine whether or not this was due 
to a change in transcription. The intensity of the bands for 
eNOS nascent transcripts was identical between proliferating 
and confluent cells, thereby providing evidence for growth-
induced regulation of eNOS expression modulated by post-
transcriptional mechanisms. By contrast, they observed a 
3-fold increase in half-life in proliferating cells compared 
with confluent cells. Ultraviolet-crosslinking analysis revealed 
a 51-kDa protein expressed 3-fold higher in confluent cells 
compared with proliferating cells. This cytosolic protein was 
found to bind to a 43-nt cis-element in the proximal 3´-UTR 
resulting in destabilization of eNOS mRNA.113
Endothelial NO activity has also been shown to be 
regulated by ROS. Hydrogen peroxide, in particular, induces 
both an elevation of eNOS protein expression and enzyme 
activity. Studies have shown that adding H2O2 to endothelial 
cells stimulates eNOS activation by PI3-kinase-Akt-  mediated 
phosphorylation of Ser1177 on eNOS.114 Drummond 
et al115 performed nuclear run-on and 5,6-dichloro-1-β-d-
ribofuranosylbenzimidazole case studies to show a 3-fold 
increase in eNOS transcription and a 2.8-fold increase in 
eNOS half-life in cells exposed to H2O2. A subsequent 
study revealed that the induction of eNOS expression by 
H2O2 was Ca2+-dependent. Immunocytochemical staining of 
BAECs revealed expression of Ca2+/calmodulin-dependent 
protein kinase II (CaM kinase II), and an in-gel kinase assay 
showed H2O2-induced autophosphorylation of CaM kinase II, 
resulting in increased eNOS activity. Cai et al116 were able to 
show that H2O2-induced activation of eNOS was dependent 
on the CaM kinase II/Janus kinase (JNK) 2 pathway. Hydro-
gen peroxide produced under shear stress has been shown to 
be regulated by PKC delta. Kumar et al117 investigated the 
mechanism by which shear stress can stimulate eNOS activity 
via PI3 kinase/Akt signaling and phosphorylation of Ser1177. 
They found that shear stress decreased PKC delta activity, 
attenuating catalase activity and increasing H2O2 signaling, 
resulting in increased eNOS phosphorylation at Ser1177 and 
NO synthesis.117 A recent study by Tian et al118 investigated 
how H2O2 affects NO activity when endothelial cells are 
subjected to shear stress. Using a small interfering RNA 
for caveolin-1, they showed decreased eNOS localization to 
the plasma membrane as well as impairment of increases in 
NO in BAECs. Caveolin-1 enhances eNOS transport to the 
plasma membrane and appears to be involved in priming 
eNOS for activation under conditions of shear stress.118
Although factors such as shear stress, cell proliferation, 
and H2O2 have been found to increase both eNOS expres-
sion and stability, hypoxia has been associated with both 
upregulation and down-regulation of eNOS expression via 
transcriptional and posttranscriptional mechanisms.119–122 
In response to hypoxia, the systemic arteries will dilate, 
allowing more blood to be delivered to peripheral tissues, 
whereas vasoconstriction will take place in the pulmonary 
system resulting in higher pulmonary pressures. This same 
trend has been shown for eNOS expression in rats exposed 
to hypoxia. Rats subjected to 10% oxygen for 12 hours, 
48 hours, or 7 days showed an 80% decrease in eNOS protein 
expression as well as eNOS mRNA expression compared 
with normoxic controls.119 Exposure to hypoxia also resulted 
in impaired capacity of aortic segments to generate cGMP 
in response to stimulation by acetylcholine. Comparison of 
eNOS expression in the left and right lungs of normoxic 
and chronically hypoxic rats resulted in a decrease in eNOS 
protein expression (32% ± 7%) and eNOS mRNA expression 
(54% ± 13%) in hypoxic lungs compared with the normoxic 
lung from the same rat.120 Thus, not only are there regional 
differences in eNOS expression in the setting of hypoxia, 
but the onset or duration of hypoxia may also affect eNOS 
expression. In lung biopsies of infants with pulmonary 
hypertension secondary to cardiac abnormalities (early stage 
of pulmonary hypertension), eNOS expression was found to 
be significantly increased in pulmonary vascular endothelial 
cells.121 This increase in eNOS expression in early stages of 
pulmonary vascular disease may represent a compensatory 
mechanism to rising pulmonary pressures. However, in the Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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setting of chronic pulmonary hypertension, there is reduced 
eNOS expression.122
Endothelial NOS activity is not always simply overex-
pressed or inhibited by certain physiological or pathophysi-
ological stimuli. As is the case with hypoxia, where regional 
differences and onset/duration of disease can affect eNOS 
expression, oxidized LDL has been shown to elicit both 
stimulatory and inhibitory responses in eNOS expression. 
Liao et al123 treated human saphenous vein endothelial cells 
with increasing concentrations of native or oxidized LDL 
and found that oxidized LDL resulted in a time-dependent 
decrease in eNOS mRNA expression. This decrease in 
eNOS mRNA expression coincided with a 56% decrease in 
NOS activity. Nuclear run-on studies revealed the complex 
nature of eNOS regulation by oxidized LDL. During the 
first 6 hours of treatment, eNOS expression was decreased 
by 25%, followed by a 2.2-fold increase in the subsequent 
18 hours. The results of this study indicate that oxidized LDL 
regulates eNOS expression through a combination of early 
transcriptional inhibition and mRNA destabilization.
vascular diseases and nitric oxide
Atherosclerosis and thrombosis
In addition to promoting endothelial dysfunction, NO insuf-
ficiency has been shown to increase atherosclerotic burden in 
vivo. Under normal conditions, NO exerts atheroprotective 
effects through several pathways, including the reduction 
of endothelial cell apoptosis and activation, via inhibition 
of nuclear factor-kappa factor (NF-κB) and inflammatory 
gene expression.124 Another way in which NO prevents 
atherogenesis is via the attenuation of leukocyte–endothelial 
cell adhesive interactions.125 BH4 deficiency, which is 
commonplace in vascular disease, has been linked to eNOS 
uncoupling in the vasculature, resulting in O2
−. production 
and NO insufficiency. A more recent study by Takaya 
et al126 highlighted the importance of BH4 availability 
in preventing eNOS uncoupling-induced atherosclerotic 
lesion progression. The authors compared atherosclerotic 
lesion progression between apolipoprotein E knockout 
(ApoE-KO)/eNOS-Tg mice treated with vitamin C and 
ApoE-KO mice crossed with mice overexpressing eNOS 
(eNOS-Tg) with mice overexpressing GTP-cyclohydrolase 
I (GCH-Tg) to produce ApoE-KO/eNOS-Tg/GCH-Tg mice. 
Atherosclerotic formation was increased in the ApoE-KO/
eNOS-Tg mice compared with ApoE-KO mice. This finding 
was attributed to uncoupled eNOS-superoxide production 
and was reversed by overexpressing GTP-cyclohydrolase I, 
the rate-limiting enzyme in BH4 synthesis.126 Endothelial 
dysfunction in hypercholesterolemia has been implicated 
in atherosclerosis progression. Several studies have shown 
a decrease of eNOS activity and expression,127,128 as well 
as its reversal with l-arginine supplementation129,130 in 
hypercholesterolemic models.
NO insufficiency, eNOS deficiency,131 and a deficiency of 
the extracellular antioxidant enzyme plasma glutathione per-
oxidase (GPx-3) in patients with vascular disease and stroke 
represent further evidence of the prothrombotic consequence 
of NO insufficiency in vivo. The first direct evidence that an 
arterial thrombotic disorder can derive from NO insufficiency 
stems from a study conducted by Freedman et al132 analyzing 
platelet inhibition by NO in 2 brothers with a cerebral throm-
botic disorder of unknown etiology. The patients were found 
to have hyperreactive platelets, a 3-fold increase in plasma 
H2O2, and decreased GPx-3 activity. GPx-3 is an enzyme that 
protects cells from oxidative damage via the reduction of 
hydrogen peroxide and lipid hydroperoxides. GPx-3 is pro-
duced primarily in the renal promixal tubules and is the only 
isoform in the GPx family that is found in the extracellular 
space. During platelet activation, specifically, activation of 
the second messenger cascade and the cytoskeletal changes 
that occur, ROS are generated.133 Hydrogen peroxide produc-
tion as a result of collage-stimulated platelet activation has 
been shown to reach concentrations up to 1 mM.134 GPx-3 
maintains NO bioavailability by preventing the accumulation 
of ROS like H2O2, allowing NO to exert an inhibitory effect 
on platelets and preventing platelet-dependent thrombosis. 
Through platelet/plasma mixing experiments, it was deter-
mined that NO bioavailability was too low to limit platelet 
activation in patient plasma. After glutathione peroxidase 
was exogenously added to the patient plasma, the inhibitory 
effects of NO were restored. We concluded that decreased 
levels of GPx-3 resulted in increase ROS flux, limiting the 
ability of NO to inhibit further platelet recruitment to the 
growing platelet thrombus (which is partly due to platelet-
derived NO135), resulting in a prothrombotic state. More 
recent studies have demonstrated an association between 
decreased GPx-3 activity in both arterial ischemic stroke136 
and cerebral venous thrombosis137 patients.
Hypertension
Endothelial dysfunction in hypertension and diabetes mellitus 
appears to be due, in part, to an imbalance in ROS genera-
tion and a decrease in NO bioavailability. This decrease in 
NO bioavailability contributes to endothelial dysfunction, 
a common property in essential hypertension138–140 and 
diabetes mellitus.141,142 Endothelial NOS plays a prominent Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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role in regulating NO bioavailability, which contributes to 
endothelial function or the lack thereof, in various vascu-
lar disease states. In most situations in which endothelial 
dysfunction occurs as a result of increased oxidative stress, 
eNOS expression is upregulated rather than decreased.143,144 
This paradoxical increase in eNOS expression is likely due 
to increased H2O2 production by the endothelium, which 
upregulates eNOS via the PI3/Akt pathway. Upregulation 
of eNOS expression in the setting of endothelial dysfunction 
shows that this increase in NO synthesis may not be sufficient 
to overcome the deleterious effects or other factors that limit 
and decrease overall NO bioavailability.
Several studies have shown that eNOS uncoupling due 
to insufficient levels of the cofactor BH4 can shift eNOS 
activity away from converting l-arginine to l-citrulline 
and NO production, toward generating O2
−. via reduction 
of molecular oxygen.145,146 Although several studies have 
shown that l-arginine supplementation improves endothelial 
dysfunction,72,147,148 physiological concentrations in plasma 
(∼100 µM)149 far exceed the Km of eNOS for l-arginine 
(∼3 µM),150,151 making substrate insufficiency an unlikely 
cause of eNOS uncoupling. As previously mentioned, BH4 
plays a critical role in eNOS activation that binds to heme 
and is involved in the electron transport-mediated release of 
NO and l-citrulline. Under conditions in which BH4 is lim-
ited, eNOS cannot transfer electrons efficiently and, instead, 
reduces molecular oxygen resulting in O2
−. production. One 
possible cause of BH4 depletion may be attributed to its reac-
tivity with OONO−. Peroxynitrite is readily formed when NO 
reacts with O2
−., which, in turn, can readily oxidize BH4 to the 
BH3 radical, resulting in eNOS uncoupling. Oxidative degra-
dation of BH4 by H2O2 and OONO− leading to the formation 
of 7,8-dihydro- l-biopterin, effectively competing for eNOS 
BH4 binding sites, also results in eNOS uncoupling.
A major source of ROS found in hypertension can be 
attributed to activity of the NADPH-oxidases. NADPH-
oxidase is a multisubunit enzyme that catalyzes the produc-
tion of O2
−. by the 1-electron reduction of O2 using NADPH 
as the electron donor. An increase in NADPH-oxidase 
activity has been implicated with regulating vascular tone 
directly or indirectly by decreasing NO bioavailability 
through O2
−. production.152,153 Several studies have shown 
an increase in NADPH-oxidase-dependent O2
−. production 
resulting in decreased NO bioavailability.154,155 Superoxide 
dismutase, an antioxidant responsible for neutralization of 
O2
−., was recently shown to prevent NADPH-oxidase-induced 
  oxidative stress in both the early stages of diabetes mellitus 
and hypertension,156 providing further evidence for redox 
imbalance contributing to endothelial dysfunction in these 
disorders.
Diabetes mellitus
As with hypertension, ROS generation and redox imbalance 
play a causative role in endothelial dysfunction in diabetes 
mellitus. Increased O2
−. levels have been reported in diabetic 
rats157,158 as well as in diabetic hypertensive patients.159 
Hyperglycemia increases O2
−. generation in endothelial 
cells.160 Possible mechanisms contributing to ROS genera-
tion under hyperglycemic conditions involve direct effects 
of glucose and free fatty acids on endothelial ROS produc-
tion, as well as via the generation of advanced glycation end 
(AGE)-products.
The activation of NADPH-oxidase has been implicated 
as a source of increased ROS formation in endothelial cells 
exposed to hyperglycemia161 as well as in hyperglycemic 
rats.162 NADPH-oxidase activation appears to occur via 
increased diacylglycerol-mediated activation of PKC161 and 
PI3-kinase-dependent activation of PKC,163 both of which 
result in ROS production. Free fatty acids also stimulate ROS 
formation in endothelial cells164,165 and appear to be associated 
with PKC activation.161 Recent studies have shown a syn-
ergistic activation of glucose-6-phosphate dehydrogenase, 
the rate limiting enzyme in the pentose phosphate pathway, 
and NADPH-oxidase resulting in increased O2
−. generation 
in type 2 diabetic rats.166,162 AGE-products are formed as a 
result of nonenzymatic glycation and oxidation of proteins, 
lipids, and polynucleotides. The receptor for advanced glyca-
tion end-products (RAGE) is a pattern recognition receptor 
that interacts with a variety of ligands. RAGE signaling 
includes the activation of NF-κB, which is associated with 
inflammation.167 In vascular endothelial cells and monocytes, 
RAGE activation results in ROS formation via NADPH-
oxidase activation. Although there are many possible causes 
of endothelial dysfunction in the setting of hypertension and 
diabetes, ROS generation, specifically O2
−., appears regulated 
principally by NADPH-oxidase activation.
Pharmacotherapies and vascular  
nitric oxide
effects of statins on nitric oxide
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors (statins) are accepted as first-line agents 
for the prevention of cardiovascular diseases associated 
with atherosclerosis. Statins lower serum cholesterol by 
inhibiting the reduction of HMG-CoA to mevalonate, the 
rate-limiting step of liver cholesterol biosynthesis.168 Statins Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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have been shown to reduce adverse cardiovascular events 
independent of the reduction of lowered serum cholesterol 
levels, suggesting additional beneficial effects of the drugs. 
These cholesterol-independent, pleiotropic effects of statins 
include improvement in endothelial function, stability of 
atherosclerotic plaques, and a decrease in oxidative stress and 
inflammation.169 In endothelial cells, inactivation of RhoA by 
statins results in increased NO biosynthesis through increased 
expression of eNOS.170 Recently, Nohria et al171 demonstrated 
that high-dose atorvastatin inhibits the Rho/Rho-associated 
kinase pathway in patients with atherosclerosis, independent 
of cholesterol reduction.
Several studies have investigated the possible mecha-
nisms by which statins increase NO bioavailability. One 
such study by Laufs et al172 investigated whether statins 
can directly upregulate eNOS activity independent of a 
decrease in serum cholesterol levels. Human saphenous 
vein endothelial cells treated with oxidized-LDL resulted in 
decreased eNOS mRNA and protein levels (91% ± 4% and 
67% ± 8%) after 72 hours.172 Treatment with either simvas-
tatin or lovastatin resulted in increased eNOS expression by 
almost 4-fold. Actinomycin treatment revealed that statins 
also increased the half-life of eNOS mRNA, supporting the 
concept that upregulation of eNOS by statins occurs via a 
posttranscriptional mechanism. Other studies showed that 
statins increased eNOS activity via activation of the PI3/Akt 
kinase pathway, resulting in upregulation of eNOS, increased 
cGMP production, and NO biosynthesis.173,174
Another mechanism by which statins restore endothelial 
function is through the inhibition of NADPH oxidase activ-
ity and uncoupled eNOS-dependent O2
−. production.175,176 
Cholesterol is a large component of caveolae, which 
constitute plasma membrane microdomains and are ubiq-
uitously present in endothelial cells.177 Caveolin-1 is a 22 
kDa protein constituent of caveolae which acts as a scaf-
folding protein that can modulate signaling of proteins 
and mediate transcytosis, transferring molecules from 
the lumen of blood vessels to the subendothelial space. 
Caveolae have been shown to be involved in the regula-
tion of eNOS, which targets to endothelial caveolae via 
N-terminal myristoylation and plamitoylation, forming an 
inhibitory complex, that renders the enzyme inactive.178 
This inhibitory complex can be reversed through increased 
Ca2+ concentrations, leading to Ca2+-calmodulin binding 
and caveolin displacement of eNOS.179 A recent study by 
Suh et al showed that rosuvastatin improved endothelial 
dysfunction in   spontaneously   hypertensive rats: the statin 
resulted in increased NOx   levels, phosphorylation of eNOS 
at Ser1177, and decreased caveolin-1 expression compared 
with controls.180
Nitrovasodilators and vascular  
nitric oxide
Nitrovasodilators have long been used in clinical settings to 
treat angina pectoris. Even though the physiological effects 
of nitrate administration is undeniably beneficial, the mecha-
nisms through which it exerts its effects on the endothelium 
and the heart are not fully understood. A number of stud-
ies have implicated several enzymes, such as glutathione 
S-transferase,181,182 oxidoreductases,183 and mitochondrial 
aldehyde dehydrogenase,184 in the bioactivation and conver-
sion of nitroglycerin to NO. Despite the extensive number 
of studies conducted, none have been able to explain the 
observation that maximal nitroglycerin-induced vasorelax-
ation occurs within minutes of administration,185 whereas 
NO produced from nitroglycerin bioactivation takes over an 
hour.186 Bonini et al recently investigated the possible role 
for eNOS-mediated vasodilation in response to nitroglycerin 
administration. In their study, the authors showed a decrease 
in systolic and diastolic pressures immediately after sub-
lingual nitroglycerin administration in rats. Treatment with 
NOS inhibitors, aminoguanidine and L-N5-(1-iminoethyl) 
ornithine dihydrochloride, inhibited average diastolic arte-
rial pressures and aortic ring relaxation compared with 
controls.187 They also showed a time course of nitroglycerin-
induced eNOS phosphorylation in HUVEC cells, which 
resulted in peak Ser1177-phosphorylation 5 minutes after 
treatment. Through their study, they suggested that eNOS 
modulation by nitroglycerin is involved in the immediate 
effects following nitroglycerin administration.
Conclusion
NO plays a versatile role in the vasculature, maintaining 
vascular tone, inhibiting or reversing platelet activity, and pre-
venting endothelial dysfunction often seen in vascular disease 
states. This highly reactive molecule contributes to vascular 
hemostasis through a variety of different pathways, with the 
classical signaling heme group-binding reaction leading to 
activation of soluble guanylyl cyclase to produce cGMP as 
a central mechanism. Not surprisingly, NO exerts its inhibi-
tory effects on platelets primarily, but not entirely, through 
cGMP generation, which, in turn, decreases intracellular 
Ca2+ concentration, GPIIb/IIIa expression, platelet fibrinogen 
binding, and platelet surface P-selectin expression. In the 
vasculature, an increase in ROS leading to NO   insufficiency 
defines the pathobiological state of oxidant stress. Oxidant Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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stress can arise from pathophysiological stimulation of 
enzymatic sources and can result in a perturbation of normal 
endothelial and platelet function. Although NO inactivation 
is primarily due to deleterious interactions with ROS within 
the vasculature, other factors limiting cofactor or substrate 
bioavailability may result in eNOS uncoupling, resulting in 
decreased NO generation. Nevertheless, despite the increas-
ing amount of information acquired since the discovery of 
endogenous NO 3 decades ago, many questions remain about 
the versatile nature of NO itself, and the complex interactions 
in which it is involved. With respect to potential new thera-
pies intended to treat disease states, such as hypertension, 
diabetes mellitus, and atherothrombosis, associated with NO 
insufficiency, more studies, both basic and clinical, are clearly 
needed to elucidate the complex role NO plays in treating or 
preventing these common disorders.
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